Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Culture Media, Conditioned/*metabolism ; Pancreatic Neoplasms/*metabolism ; Proteomics/*methods ; Serum/*metabolism; Animals ; Biomarkers, Tumor/metabolism ; Cricetinae ; Gene Expression Regulation, Neoplastic ; Gene Ontology ; Genes, Neoplasm ; Humans ; Neoplasm Proteins/metabolism ; Pancreatic Neoplasms/genetics ; Protein Binding ; Proteome/metabolism ; Reproducibility of Results ; Signal Transduction ; Survival Analysis ; Tumor Cells, Cultured

Pancreatic cancer is a highly metastatic and chemo-resistant disease. Secreted proteins involved in cell-cell interactions play an important role in changing the tumor microenvironment. Previous studies generally focus on the secretome of cancer cell line from serum-free media, due to the serious interference of fetal bovine serum (FBS). However, serum-starvation may alter expression patterns of secreted proteins. Hence, efforts to decrease the interference of serum in proteomic analysis of serum-containing media have been hampered to quantitatively measure the tumor secretion levels. Recently, the metabolic labeling, protein equalization, protein fractionation and filter-aided sample preparation (FASP) strategy (MLEFF) has been successfully used to avoid the disturbance of serum on secretome analysis. Here, this efficient method was applied for comparative secretome analysis of two hamster pancreatic cancer cells with differentially metastatic potentials, enabling the observation of 161 differentially expressed proteins, including 106 proteins that had been previously reported and detected in plasma. By integrated analysis of our data and publicly available bioinformatics resources, we found that a combination panel consisting of CDH3, PLAU, and LFNG might improve the prognosis of overall pancreatic cancer survival. These secreted proteins may serve as a potential therapeutic targets for pancreatic cancer metastasis.

Am J Pathol. 1991 Mar;138(3):557-61. (PMID: 2000935)
Oncol Rep. 2010 Jul;24(1):251-5. (PMID: 20514469)
Carcinogenesis. 1989 May;10(5):861-9. (PMID: 2539915)
Nat Med. 2013 Nov;19(11):1423-37. (PMID: 24202395)
Mol Cell Proteomics. 2015 Mar;14(3):471-83. (PMID: 25527621)
Exp Ther Med. 2010 Jan;1(1):211-216. (PMID: 23136617)
Int J Oncol. 2004 Jan;24(1):65-73. (PMID: 14654942)
Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900)
Clin Cancer Res. 2014 Nov 15;20(22):5787-95. (PMID: 25239611)
Protein Eng Des Sel. 2004 Apr;17(4):349-56. (PMID: 15115854)
Anal Chem. 2016 May 3;88(9):4971-8. (PMID: 27042867)
Mol Cell Proteomics. 2011 Sep;10(9):M110.006353. (PMID: 21632744)
J Proteomics. 2010 Nov 10;73(12):2291-305. (PMID: 20637910)
Nat Methods. 2011 Sep 29;8(10):785-6. (PMID: 21959131)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
J Neurochem. 2000 Apr;74(4):1478-88. (PMID: 10737604)
Nat Biotechnol. 2012 Oct;30(10):984-90. (PMID: 23000932)
Gut. 2015 Sep;64(9):1476-84. (PMID: 25994217)
Int J Oncol. 2006 Feb;28(2):369-74. (PMID: 16391791)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
Proteomics. 2015 Aug;15(15):2597-601. (PMID: 25921073)
Cancer Res. 2011 Nov 15;71(22):7091-102. (PMID: 21948970)
Cancer Lett. 2016 Jan 1;370(1):33-8. (PMID: 26458996)
J Mol Biol. 2016 Feb 22;428(4):688-92. (PMID: 26434508)
Nucleic Acids Res. 2016 Jan 4;44(D1):D336-42. (PMID: 26578592)
Nat Methods. 2009 May;6(5):359-62. (PMID: 19377485)
Clin Cancer Res. 2008 Oct 15;14(20):6487-95. (PMID: 18927288)
Carcinogenesis. 1993 Feb;14(2):259-64. (PMID: 8382114)
Nat Methods. 2016 Sep;13(9):731-40. (PMID: 27348712)
Nat Protoc. 2009;4(1):44-57. (PMID: 19131956)
J Biol Chem. 2000 Aug 11;275(32):24984-92. (PMID: 10827079)
J Proteome Res. 2010 Sep 3;9(9):4376-92. (PMID: 20687567)
Nature. 2014 May 29;509(7502):575-81. (PMID: 24870542)
PLoS One. 2016 Mar 25;11(3):e0152280. (PMID: 27014871)
Oncogene. 2016 May 12;35(19):2485-95. (PMID: 26279302)

0 (Biomarkers, Tumor)
0 (Culture Media, Conditioned)
0 (Neoplasm Proteins)
0 (Proteome)

Date Created: 20161122 Date Completed: 20180521 Latest Revision: 20220330

20240829

PMC5116583

10.1038/srep37606

27869176